UTRS · Minerva Surgical Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $50.29M | $37.77M |
| Cost of Revenue | $23.05M | $18.65M |
| Gross Profit | $27.24M | $19.12M |
| R&D | $5.44M | $3.32M |
| SG&A | $14.37M | $8.21M |
| Total Operating Expenses | $58.14M | $34.51M |
| D&A | $2.60M | $2.00M |
| Operating Income | ($30.90M) | ($15.39M) |
| Interest Expense | $3.22M | $12.14M |
| Income Tax | $11.0K | ($132.0K) |
| Net Income | ($34.11M) | ($18.26M) |
| EPS - Basic | ($61.20) | - |
| EPS - Diluted | ($61.20) | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $6.94M | $40.61M |
| Accounts Receivable | $7.24M | $7.29M |
| Inventory | $16.85M | $15.68M |
| Accounts Payable | $2.80M | $3.63M |
| Current Assets | $36.12M | $75.00M |
| Total Assets | $68.90M | $115.09M |
| Current Liabilities | $14.28M | $22.81M |
| Long-term Debt | $37.44M | $39.09M |
| Total Liabilities | $51.72M | $70.99M |
| Stockholders' Equity | $17.18M | $44.10M |
| Retained Earnings | ($283.67M) | ($249.56M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($35.57M) | ($12.24M) |
| Investing Cash Flow | ($73.0K) | ($15.45M) |
| Financing Cash Flow | ($4.96M) | $18.08M |
| CapEx | $73.0K | $453.0K |
| Free Cash Flow | ($35.64M) | ($12.69M) |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | 54.2% | 50.6% |
| Operating margin | -61.4% | -40.7% |
| EBITDA margin | -56.3% | -35.5% |
| Net margin | -67.8% | -48.4% |
| Free cash flow margin | -70.9% | -33.6% |
| FCF / Net income | 1.04 | 0.70 |
| R&D / Revenue | 10.8% | 8.8% |
| SG&A / Revenue | 28.6% | 21.7% |
| Effective tax rate | - | - |
| Return on assets | -49.5% | -15.9% |
| Return on equity | -198.5% | -41.4% |
| Return on invested capital | -44.7% | -14.6% |
| Liquidity | ||
| Current ratio | 2.53 | 3.29 |
| Quick ratio | 1.35 | 2.60 |
| Cash ratio | 0.49 | 1.78 |
| Leverage | ||
| Debt / Equity | 2.18 | 0.89 |
| Debt / Assets | 0.54 | 0.34 |
| Debt / EBITDA | - | - |
| Interest coverage | -9.6x | -1.3x |
| Equity multiplier | 4.01 | 2.61 |
| Liabilities / Assets | 0.75 | 0.62 |
| Efficiency | ||
| Asset turnover | 0.73 | 0.33 |
| Inventory turnover | 1.37 | 1.19 |
| Days sales outstanding | 53d | 70d |
| Days inventory outstanding | 267d | 307d |
| Days payable outstanding | 44d | 71d |
| Cash conversion cycle | 275d | 306d |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | 33.2% | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | 42.5% | - |
| Operating income growth (YoY) | -100.8% | - |
| Net income growth (YoY) | -86.8% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -180.8% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -61.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$100.0K totalWarranty Service$100.0K · 100.0%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-3.79
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing MINERVA SURGICAL INC against the 5 most active filers in the same SIC group.